As dual-agonism may provide superior glucoregulatory and anti-obesity effects to mono-agonists [104], there have been attempts to modify the peptide sequence of OXM for more balanced dual agonism for GLP-1R and GCGR. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.